Prognostic models in the myeloproliferative neoplasms.
Essential thrombocythemia
Genomics
Myelofibrosis
Myeloproliferative neoplasms
Polycythemia vera
Prognostic modelling
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
28
12
2019
revised:
25
02
2020
accepted:
27
05
2020
pubmed:
14
6
2020
medline:
20
1
2021
entrez:
14
6
2020
Statut:
ppublish
Résumé
The management of myelofibrosis (MF) is predominantly supportive, with the use of JAK2 inhibitors or allogeneic stem cell transplantation reserved for patients predicted to have poor overall survival. Identification of these patients is aided by a number of prognostic scoring systems, foremost among them the Dynamic International Prognostic Scoring System (DIPSS). Similarly, the use of cytoreductive therapies in essential thrombocytosis (ET) and polycythemia vera (PV) is targeted to patients identified as at highest risk of thrombosis. In this context, age and history of prior thrombosis are the strongest risk factors. Several studies have sought to improve the accuracy of prognostic modelling by encorporating a wider range of clinical and genomic variables, while also assessing those predictive for other endpoints, such as disease transformation. This review aims to summarise and evaluate existing prognostic models in the myeloproliferative neoplasms, and examine ways in which they can be further refined.
Identifiants
pubmed: 32532453
pii: S0268-960X(20)30063-1
doi: 10.1016/j.blre.2020.100713
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100713Informations de copyright
Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.